Drug Type Small molecule drug |
Synonyms ICG-001, OP-724, PRI-724 |
Target |
Mechanism CTNNB1 inhibitors(Catenin beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H32N4O4 |
InChIKeyHQWTUOLCGKIECB-XZWHSSHBSA-N |
CAS Registry780757-88-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 2 | JP | 16 Aug 2018 | |
Hepatitis B | Phase 2 | JP | 24 Jul 2018 | |
Hepatitis B | Phase 2 | JP | 24 Jul 2018 | |
Hepatitis C | Phase 2 | JP | 24 Jul 2018 | |
Hepatitis C | Phase 2 | JP | 24 Jul 2018 | |
Acidemia, Isovaleric | Phase 2 | US | 01 Nov 2015 | |
Adenocarcinoma of large intestine | Phase 2 | US | 01 Nov 2015 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 Nov 2015 | |
Acute Myeloid Leukemia | Phase 2 | US | 01 Jul 2012 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | US | 01 Jul 2012 |
NCT04047160 (Pubmed) Manual | Phase 1 | 7 | pgcrtrtbwf(etjwkpvsfj) = dlxrxvudhd qfrwfbqwwy (bjypocxpct ) View more | Positive | 01 Nov 2022 | ||
NCT03620474 (Pubmed) Manual | Phase 1/2 | 27 | (phase 1) | - | Positive | 20 May 2022 | |
(phase 2a) | corlawzjtr(uqylczbooc) = pfiqcitgij hflhtdabli (oumgcrvmqh ) View more | ||||||
NCT01764477 (ASCO2016) Manual | Phase 1 | Advanced Pancreatic Adenocarcinoma Second line | 20 | gemcitabine+PRI-724 | barfnhrlkc(uyfxpdzuzc) = none muqlvlctsk (mqnaiymsld ) View more | Positive | 03 Jun 2016 |
Phase 1 | Advanced Pancreatic Adenocarcinoma Second line | 10 | vqwhoxhded(zqumawkxza) = aytkxujumu fmobfzmldd (euvqemuuzh ) | - | 20 May 2015 | ||
Phase 1 | 18 | nkkzficzbv(ujqvlxzwzk) = roigjduyje ugrckxqxwp (ycandvxnbw ) View more | - | 20 May 2013 |